MiMedx Group, Inc.
HealthcareNASDAQ:MDXG · NASDAQ Capital Market
-$0.09 today
Vol 0.95M · Avg 1.52M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
18.9%
avg -2.8%
ROIC
16.7%
avg 5.8%
ROA
14.2%
avg 4.7%
Analysis
ROE is currently the strongest return metric at 18.9% versus its period average of -2.8%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph H. Capper | Chief Executive Officer & Director | $1.66M | — | 62 | $904,656.00 | 0.61% |
William F. Hulse | General Counsel & Chief Administrative Officer | $997,673.00 | — | 52 | $254,931.00 | 0.17% |
Douglas C. Rice | Chief Financial Officer | $984,521.00 | — | 60 | $412,315.00 | 0.28% |
Kimberly Maersk-Moller | Chief Commercial Officer | $921,641.00 | — | 59 | $329,450.00 | 0.22% |
Robert Benjamin Stein | President of Regenerative Medicine & Biologics Innovation | $639,284.00 | — | 75 | $317,803.00 | 0.21% |
Rebeccah J. Covert Brown | Vice President of Global Regulatory Affairs | $179,840.00 | — | 53 | $273,530.00 | 0.18% |
Tracy Chastain | Chief Human Resources Officer | — | — | — | — | — |
Eric A. Smith | Senior VP of Marketing & International | — | — | 54 | — | — |
Matthew Notarianni | Head of Investor Relations | — | — | — | $0.00 | <0.01% |
David H. Mason Jr. | Chief Medical Officer | — | — | 79 | $0.00 | <0.01% |
John Harper | SVP of R&D & Medical Affairs and Chief Scientific Officer | — | — | — | — | — |
Mark Graves | Senior Vice President & Chief Compliance Officer | — | — | 60 | $133,608.00 | 0.09% |
Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications | — | — | — | — | — |
Kate Surdez | Chief Human Resources Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$432,329.48
Net Sentiment
$432,329.48
Net selling
Most Active
Maersk-Moller Kimberly
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $432,329.48 over the last 12 months. That adds up to net selling of $432,329.48. Maersk-Moller Kimberly was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +3.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +90.6% | +5.6% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | +5.5% (15yr)1 analysts |
| EBIT | N/A | N/A | N/A | +1.6% (15yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +90.6% over three years. Forward estimates point to Revenue at +5.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Innoviva, Inc.
NASDAQ:INVA
$1.68B
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
$1.64B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
$1.40B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Who manages MDXG?
MiMedx Group, Inc. (MDXG) lists 14 active executives. The top listed executive is Kimberly Maersk-Moller, Chief Commercial Officer.
Are MDXG insiders buying or selling?
Recent insider activity shows net buying of $34.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.